Skip to main content

Table 2 Expression analysis of NDRG2 in colon cancer using a Cancer Profiling Array.

From: Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma

Sample Signal intensity Tumor/normal TNM staging Age Gender
Tumor/normal 18370/60015 0.31 II; T4N0M0 67 Female
Tumor/normal 31402/35431 0.89 I; T1N0M0 58 Female
Tumor/normal 57125/96121 0.59 IV; T4N0M0 43 Female
Tumor/normal 20382/23650 0.86 IIIB; T3N1M0 69 Female
Tumor/normal 28165/59167 0.48 IIIB; T3N1M0 35 Female
Tumor/normal 22193/12912 1.72 IIIA; T4N0M0 58 Male
Tumor/normal 18569/28122 0.66 IIIB; T4N1M0 63 Male
Tumor/normal 9863/28914 0.34 IIA; T2N0M0 73 Female
Tumor/normal 21780/34774 0.63 IIIB; T4N0M? 65 Female
Tumor/normal 22429/45939 0.49 IIIA; T3N1M0 65 Female
  1. Expression of NDRG2 mRNA was determined by hybridisation of a Cancer Profiling Array with a NDRG2 probe. Quantification of the hybridisation signal for the paired samples revealed that NDRG2 expression was reduced in 9 out of 10 colon tumor samples compared to the corresponding normal sample. Using a two-tailed paired t-test, the decrease in NDRG2 expression in tumors compared to normal samples was found to be statistically significant (p < 0.01). The tumors were all diagnosed as adenocarcinoma aside from the Stage I tumor which was a tubulovillous adenoma. The TNM staging system describes the extent of the primary tumor (T), the absence/presence of metastasis to nearby lymph nodes (N) and the absence/presence of distant metastases (M).